Answers are grounded in this paper and cite their sources.
Glaucoma is the leading cause of irreversible blindness worldwide. Current first-line therapies frequently yield suboptimal intraocular pressure (IOP) control. Furthermore, many patients develop progressive visual field loss despite adequate pressure management. To address this gap, we developed a class of first-in-class dual-target inhibitors against carbonic anhydrase II (CA II) and Rho-associated coiled-coil-containing protein kinase (ROCK). Among them, A3 showed 6250-fold higher hCA II inhibitory potency than the initial fragment with favorable selectivity and 1.2-/1.7-fold higher ROCK1/2 inhibitory activity than fasudil. In vivo, A3 produced potent and sustained IOP reduction across multiple models. Notably, in the DBA/2J spontaneous glaucoma model, it potently lowered IOP and preserved retinal structural integrity. Meanwhile, A3 attenuated retinal ganglion cell apoptosis via its antioxidant and anti-inflammatory effects, thereby conferring optic neuroprotection with favorable systemic safety. Overall, A3 overcomes key limitations of current antiglaucoma drugs and represents a promising candidate for combined IOP-lowering and optic neuroprotective therapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: